Fosun Pharma Buys $22.4 Million of Saladax Stock
publication date: Mar 4, 2013
Shanghai Fosun Pharma has agreed to buy $22.4 million of Series D preferred shares in Saladax Biomedical, a US maker of diagnostic assays. Also, Fosun will have the right to distribute Saladax products in mainland China. Saladax produces the MyCare™ family of oncology assays, which allows doctors to optimize dosing of specific medicines despite individual differences in absorption and clearance. Using the tests, a physician can obtain the blood concentration of the drug that combines a high therapeutic result with minimal side effects. More details....
Stock Symbols:(SHA: 600196; HK: 02196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.